Products

• Lazanda^® (fentanyl nasal spray) for the management of breakthrough pain in cancer patients ages 18 years or older who are receiving and who are tolerant to opioid therapy for their underlying cancer pain (PI). For more information visit www.Lazanda.com
• PecFent^® (fentanyl pectin nasal spray) for the management of breakthrough pain (BTP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. For more information visit www.PecFent.com.

Breakthrough pain in cancer (BTPc) is an intense, sudden pain that is often unpredictable and debilitating and occurs despite otherwise appropriate opioid therapy for background pain. BTPc has a different profile from background pain. BTPc often has high intensity, a rapid onset, usually reaching maximum intensity within five minutes, and a short duration, lasting between 30 to 60 minutes per episode. On average, BTPc affects more than half of patients with cancer and often interferes with patients’ health and ability to engage in daily living activities.

• Gliadel^® implant (carmustine) View the SmPC
• Zomorph^® capsule (morphine sulphate) View the SmPC
• Oramorph^® oral solution (morphine sulphate) View the SmPC
• Apomorphine injection (apomorphine HCl) View the SmPC
• Pabrinex^® injection (high potency formulation of vitamins B and C) View the SmPC